Cyprotex Launches New Cloe(R) Screen Assay to Improve the Prediction of in vivo Pharmacokinetics

Cyprotex Launches New Cloe(R) Screen Assay to Improve the Prediction of in vivo Pharmacokinetics

June 07, 2007

    MANCHESTER, England, June 7 /Xinhua-PRNewswire/ --
Cyprotex announces that it has enhanced the Cloe(R) Screen
product offering to include an in vitro assay that assesses
the extent to which a compound binds to liver microsomes.
When used in conjunction with microsomal stability data,
correction for microsomal binding can improve the
prediction of a compound's in vivo clearance and potential
for drug-drug interactions. The Cyprotex Cloe(R) Screen
microsomal binding assay was designed in response to
requests from biotechnology and pharmaceutical companies
who work with Cyprotex' to evaluate potential drug
candidates.

    Mr. Robert Morrison Atwater, Cyprotex' Chief Executive
Officer, comments on the launch of the new service 'Once
again Cyprotex proves itself to be foremost in the
provision of in vitro ADMET services. By offering this
service we are adding to our extensive portfolio of
services and reinforcing Cyprotex' position as a leader
within the industry. Similarly to existing Cloe(R) Screen
assays, the microsomal binding assay is invaluable in
enabling companies to make informed decisions when
selecting compounds to progress further within the drug
discovery process.'

    Cyprotex is a specialist provider of ADME data and
pharmacokinetic predictive services. The unique Cloe(R)
Screen technology which couplesrobust protocols with
state-of-the-art automation enables Cyprotex to offer an
unrivalled combination of high quality, cost effective data
with rapid turnaround. By using data from the Cloe(R) Screen
microsomal binding assay in conjunction with the existing
Cloe(R) Screen microsomal stability, a more accurate
prediction of the rate at which a drug is metabolised in
vivo is determined than by means of microsomal stability
data alone. The data can also be applied to improving in
vivo drug-drug interaction predictions.



    For more information, please contact:

     Dr. Francesca Sadler
     Marketing Manager, Cyprotex PLC
     Tel:   [phone]
     Email: [e-mail]
     Web:   http://www.cyprotex.com